{"gene":"FRG1","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1996,"finding":"FRG1 is a novel gene located ~100 kb proximal to the D4Z4 repeat on chromosome 4q35, encoding a 258 amino acid protein with a CpG island at its 5' UTR; allele-specific RNA-SSCP analysis found no evidence for position-effect variegation-mediated repression of FRG1 transcription in FSHD lymphocytes or muscle.","method":"Molecular cloning, genomic mapping, RNA-SSCP allele-specific expression analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — original identification with multiple molecular methods (cloning, mapping, SSCP), single lab, foundational characterization","pmids":["8733123"],"is_preprint":false},{"year":1998,"finding":"FRG1 protein contains a lipocalin sequence motif, suggesting it may function as a transport protein; the intron/exon structure of FRG1 is conserved across vertebrates (human, mouse, Fugu) and nematodes (C. elegans, Brugia malayi).","method":"Comparative genomic cloning, sequence alignment, motif analysis","journal":"Gene","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational/sequence-based motif prediction only, no functional validation of transport activity","pmids":["9714712"],"is_preprint":false},{"year":2005,"finding":"Transgenic mice selectively overexpressing FRG1 in skeletal muscle develop a muscular dystrophy with features characteristic of FSHD, including aberrant alternative splicing of specific pre-mRNAs in both FRG1 transgenic mouse muscle and FSHD patient muscle; FRG1 is a nuclear protein implicated in pre-mRNA splicing. Overexpression of FRG2 or ANT1 did not produce this phenotype.","method":"Transgenic mouse generation (skeletal muscle-specific overexpression), histopathology, RT-PCR splicing analysis, nuclear localization by immunostaining","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple transgenic lines with genetic controls (FRG2, ANT1 transgenics), replicated in human FSHD patient samples, two orthogonal readouts (muscle phenotype + splicing)","pmids":["16341202"],"is_preprint":false},{"year":2009,"finding":"Endogenous frg1 in Xenopus is expressed in developing and adult vasculature; frg1 knockdown reduces angiogenesis and decreases expression of the angiogenic regulator DAB2, while frg1 overexpression causes increased blood vessel branching, dilation, and edema.","method":"Xenopus morpholino knockdown, overexpression, in vivo angiogenesis assay, DAB2 expression analysis","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function in Xenopus with defined vascular phenotype and downstream target (DAB2), single lab","pmids":["19383939"],"is_preprint":false},{"year":2009,"finding":"frg1 is expressed in Xenopus tadpole musculature and is essential for myotome development; morpholino-mediated frg1 knockdown disrupts myotome organization and inhibits myotome growth, while FRG1 overexpression causes abnormal epaxial and hypaxial muscle formation.","method":"Xenopus morpholino knockdown, mRNA overexpression, histological analysis of myotome","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal loss-of-function and gain-of-function with defined morphological readout, single lab","pmids":["19097195"],"is_preprint":false},{"year":2009,"finding":"The FRG1 gene promoter and the D4Z4 array physically interact in cis, as demonstrated by chromosome conformation capture (3C); this chromatin loop undergoes dynamic changes during myogenic differentiation (loosening in myotubes). FRG1 promoter is marked by H3K27 trimethylation and Polycomb repressor complex binding in myoblasts, replaced by H3K4 trimethylation upon differentiation. FRG1 is prematurely expressed during FSHD myoblast differentiation.","method":"Chromosome conformation capture (3C), ChIP for H3K27me3, H3K4me3, Polycomb complex; RT-PCR expression analysis","journal":"BMC biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3C plus ChIP with multiple histone marks, single lab, multiple orthogonal methods","pmids":["19607661"],"is_preprint":false},{"year":2010,"finding":"C. elegans FRG-1 and human FRG1 are F-actin-bundling proteins; C. elegans FRG-1 localizes to two subcellular pools: nuclear (nucleolar) and cytoplasmic (Z-disk/dense body structures). Overexpressed FRG-1 preferentially accumulates in the nucleus and, when overexpressed from the frg-1 promoter, disrupts adult ventral muscle structure and organization.","method":"In vitro F-actin bundling assay (with both C. elegans and human FRG1), immunofluorescence localization in C. elegans body-wall muscle, transgenic C. elegans overexpression","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro actin bundling assay directly demonstrated for both C. elegans and human FRG1, complemented by subcellular localization and in vivo functional data in C. elegans","pmids":["20215405"],"is_preprint":false},{"year":2011,"finding":"FRG1 is a dynamic nuclear and cytoplasmic protein in mammalian cells; nuclear shuttling assays show the subcellular pools are linked. During myoblast differentiation, FRG1 redistributes to mature Z-discs, as confirmed in isolated mouse myofibers and adult human skeletal muscle biopsies. FRG1 is also strongly expressed in arteries, veins, and capillaries.","method":"Immunocytochemistry, nuclear shuttling assay (heterokaryon or similar), isolated myofiber immunostaining, human muscle biopsy histology","journal":"Differentiation; research in biological diversity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by ICC plus nuclear shuttling assay with functional context (sarcomere association), validated in mouse and human tissue, single lab","pmids":["20970242"],"is_preprint":false},{"year":2011,"finding":"FRG1 overexpression in C2C12 myoblasts reduces pRb phosphorylation, increases G1-phase cells, and increases doubling time; myoblasts from dystrophic (thigh) muscle of FRG1 transgenic mice show decreased proliferative capacity, while myoblasts from unaffected (diaphragm) muscle proliferate normally.","method":"Inducible FRG1 overexpression in C2C12, flow cytometry cell cycle analysis, pRb phosphorylation by western blot, clone-size assay from primary myoblasts","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent cell systems (inducible C2C12 and primary myoblasts), cell cycle analysis with molecular correlate (pRb phosphorylation), single lab","pmids":["21603621"],"is_preprint":false},{"year":2013,"finding":"FRG1 overexpression reduces Rbfox1 RNA stability, leading to downregulation of Rbfox1 protein; this results in aberrant splicing of Rbfox1 target genes including Calpain 3 (increased exon-6-skipped isoform Capn3 E6-). FRG1 was found to be associated with Rbfox1 RNA by RNA-IP. Rbfox1 knockdown and Capn3 E6- overexpression each inhibit muscle differentiation.","method":"RNA-IP (FRG1 association with Rbfox1 RNA), genome-wide splicing analysis, Rbfox1 knockdown, RT-PCR splicing assays, muscle differentiation assays, FSHD patient validation","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — RNA-IP plus genome-wide splicing analysis plus knockdown/overexpression rescue experiments, validated in FSHD patient samples, multiple orthogonal methods in single lab","pmids":["23300487"],"is_preprint":false},{"year":2013,"finding":"FRG1-overexpressing mice develop aberrant splicing of Tnnt3 (fast skeletal troponin T), producing anomalous fTnT isoforms before dystrophic signs appear; fast-twitch fibers in these mice show reduced Ca2+ sensitivity that can be rescued by substitution with wild-type troponin complex proteins. Aberrant TNNT3 splicing isoforms are also present in FSHD patient muscles.","method":"RT-PCR splicing analysis, muscle contractility/Ca2+ sensitivity assay, protein substitution rescue experiment, FSHD patient sample validation","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution/substitution rescue of Ca2+ sensitivity, combined with splicing analysis and human patient validation, multiple orthogonal methods","pmids":["24305066"],"is_preprint":false},{"year":2015,"finding":"FRG1 overexpression causes a myoblast fusion defect in C2C12 cells; crossing FRG1 transgenic mice with FHL1 transgenic mice (which promote myoblast fusion) rescues the dystrophic phenotype (reduced kyphosis, increased muscle mass, decreased fibrosis) without altering satellite cell number or activation, establishing that impaired myoblast fusion contributes to FRG1-mediated dystrophy.","method":"Stable C2C12 overexpression, transgenic cross (FRG1 x FHL1 mice), histopathology, satellite cell analysis, primary myoblast fusion assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via transgenic cross with defined cellular mechanism (myoblast fusion), validated in primary cells and in vivo, single lab","pmids":["25695429"],"is_preprint":false},{"year":2022,"finding":"FRG1 directly binds the GM-CSF promoter to repress its transcription; FRG1 depletion increases GM-CSF expression, which activates the MEK/ERK axis and inhibits p53-dependent apoptosis in breast cancer cells in an ERK-dependent manner.","method":"ChIP, promoter reporter assay, western blot (MEK/ERK, p53), GM-CSF knockdown rescue, mouse xenograft model, anti-GM-CSF mAb treatment","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct FRG1 binding to GM-CSF promoter, functional pathway validated by pharmacological inhibition and in vivo xenograft, single lab","pmids":["36329016"],"is_preprint":false},{"year":2022,"finding":"FRG1 acts as a transcriptional regulator of nonsense-mediated mRNA decay (NMD) pathway genes (UPF1, UPF3B, SMG1) by binding to a conserved 'CTGGG' motif in their promoters; this was established by structural modeling, EMSA, ChIP-qPCR, and luciferase reporter assays.","method":"Microarray expression profiling, structural modeling, EMSA, ChIP-qPCR, luciferase reporter assay, site-directed mutagenesis (predicted binding site)","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (EMSA, ChIP, luciferase, mutagenesis) supporting direct DNA binding and transcriptional regulation, single lab","pmids":["36521634"],"is_preprint":false},{"year":2023,"finding":"FRG1 depletion in breast cancer cells activates FGF2 expression, which in turn triggers ERK/AKT signaling in endothelial cells (HUVECs) to enhance proliferation, migration, and tubule formation in a paracrine manner; this pro-angiogenic effect was validated in multiple animal models.","method":"HUVEC co-culture paracrine assay, FGF2 expression analysis, western blot (ERK/AKT), FRG1 knockdown, in vivo animal angiogenesis models","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — paracrine mechanism with defined intermediary (FGF2) validated in multiple animal models, single lab, mechanistic pathway defined by signaling analysis","pmids":["36815234"],"is_preprint":false},{"year":2024,"finding":"FRG1 transcription is regulated by Sp1 (activator), YY1 (repressor), and DUX4 (activator) binding to cis-regulatory elements in the FRG1 promoter; YY1 can suppress Sp1- or DUX4-mediated FRG1 transcription activation, while Sp1 and DUX4 together counteract YY1-mediated repression. Sp1, YY1, and DUX4 physically interact with each other at the FRG1 promoter.","method":"Dual luciferase reporter assay, site-directed mutagenesis, ChIP-qPCR, EMSA, sequential ChIP (ChIP re-ChIP), co-immunoprecipitation, mouse xenograft model","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (EMSA, ChIP, co-IP, mutagenesis, reporter assay) establishing direct binding and functional interactions, single lab","pmids":["39708975"],"is_preprint":false},{"year":2024,"finding":"FRG1 affects transcription of DNA base excision repair (BER) genes including HPF1; breast cancer cells with reduced FRG1 show diminished DNA repair capacity as measured by Alkaline Comet Assay, and FRG1-low breast cancers have higher TP53 mutation frequency.","method":"qRT-PCR, Alkaline Comet Assay, bioinformatic analysis of mutation frequency","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, Comet Assay provides functional readout but mechanism linking FRG1 to BER gene transcription not directly demonstrated; indirect evidence only","pmids":["39169067"],"is_preprint":false},{"year":2025,"finding":"FRG1 is a structural component of both the spliceosome and the exon junction complex (EJC), co-sedimenting with the core EJC component eIF4A3 in polysome fractions; FRG1 directly interacts with UPF1 and regulates its ubiquitination and degradation, thereby modulating NMD activity. Reduced FRG1 enhances NMD activity. DUX4 inversely regulates NMD machinery through FRG1. Absence of FRG1 does not compromise EJC or spliceosome integrity. These findings were validated in a transgenic FRG1 knockout zebrafish model.","method":"Polysome profiling, proximity ligation assay (FRG1-eIF4A3 interaction), co-immunoprecipitation (FRG1-UPF1), ubiquitination assay, NMD reporter assay, FRG1 knockout zebrafish in vivo validation","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — preprint with multiple orthogonal methods (polysome profiling, PLA, Co-IP, ubiquitination assay, in vivo zebrafish KO), single lab, not yet peer-reviewed","pmids":["bio_10.1101_2025.11.18.689056"],"is_preprint":true}],"current_model":"FRG1 is a dual-compartment protein (nuclear and sarcomeric/cytoplasmic) that functions in pre-mRNA splicing and post-transcriptional regulation: it directly bundles F-actin at Z-discs/dense bodies, associates with the spliceosome and exon junction complex (interacting with eIF4A3 and UPF1 to modulate nonsense-mediated mRNA decay), regulates alternative splicing of muscle-specific transcripts (e.g., TNNT3, Calpain 3) partly by destabilizing the splicing regulator Rbfox1, acts as a transcriptional repressor of cytokines (GM-CSF) and NMD pathway genes via direct promoter binding, and controls angiogenesis through a FGF2-ERK/AKT paracrine axis; its overexpression in skeletal muscle causes FSHD-like muscular dystrophy via aberrant splicing and impaired myoblast fusion, while its transcription is controlled by the interplay of Sp1 (activator), YY1 (repressor), and DUX4 (activator) at its promoter."},"narrative":{"mechanistic_narrative":"FRG1 is a dual-compartment protein that couples cytoskeletal organization to post-transcriptional gene regulation, and its dysregulation underlies muscle and vascular pathology [PMID:16341202, PMID:20215405, PMID:23300487]. In the cytoplasm it directly bundles F-actin and localizes to Z-disc/dense-body structures, redistributing to mature Z-discs during myoblast differentiation [PMID:20215405, PMID:20970242]. In the nucleus FRG1 participates in pre-mRNA splicing and post-transcriptional control: it associates with Rbfox1 RNA and destabilizes it, driving aberrant alternative splicing of muscle transcripts including Calpain 3 and the fast troponin T gene Tnnt3, the latter producing fibers with reduced Ca2+ sensitivity [PMID:23300487, PMID:24305066]. FRG1 also acts as a sequence-specific transcriptional regulator, binding the GM-CSF promoter to repress cytokine expression and ERK signaling, and binding a conserved CTGGG motif in the promoters of NMD genes UPF1, UPF3B and SMG1 [PMID:36329016, PMID:36521634]. Selective overexpression of FRG1 in skeletal muscle causes an FSHD-like muscular dystrophy with aberrant splicing recapitulated in FSHD patient muscle, mechanistically attributable to impaired myoblast fusion, since restoring fusion via FHL1 rescues the dystrophic phenotype [PMID:16341202, PMID:25695429]. FRG1 transcription is itself controlled by competing promoter factors Sp1, YY1 and DUX4 that physically interact at the FRG1 promoter, and the FRG1 promoter loops to the D4Z4 array in a differentiation-dependent manner [PMID:39708975, PMID:19607661]. FRG1 additionally controls angiogenesis through a paracrine FGF2-ERK/AKT axis [PMID:36815234, PMID:19383939].","teleology":[{"year":1996,"claim":"Establishing FRG1 as a defined gene near the FSHD-associated D4Z4 repeat created the genomic entry point, while showing its transcription is not silenced by position effect in patient tissue.","evidence":"Molecular cloning, genomic mapping, and allele-specific RNA-SSCP in FSHD lymphocytes and muscle","pmids":["8733123"],"confidence":"Medium","gaps":["No protein function assigned","Relationship between FRG1 and FSHD pathogenesis not yet tested"]},{"year":2005,"claim":"Asking whether FRG1 itself could drive FSHD pathology, muscle-specific overexpression in mice produced a dystrophy with aberrant splicing matching FSHD patient muscle, implicating FRG1 in pre-mRNA splicing.","evidence":"Skeletal-muscle-specific transgenic mice with FRG2/ANT1 transgenic controls, histopathology, RT-PCR splicing analysis, nuclear immunostaining","pmids":["16341202"],"confidence":"High","gaps":["Molecular splicing target not yet identified","Mechanism connecting FRG1 to spliceosome unknown"]},{"year":2009,"claim":"Vertebrate and chromatin studies expanded FRG1 beyond muscle, showing roles in angiogenesis and myotome development and that its promoter loops to D4Z4 with differentiation-dependent histone marks.","evidence":"Xenopus morpholino knockdown/overexpression with vascular and myotome readouts; 3C and ChIP for H3K27me3/H3K4me3/Polycomb in myoblasts","pmids":["19383939","19097195","19607661"],"confidence":"Medium","gaps":["Whether vascular and muscle roles share a molecular mechanism unresolved","Functional consequence of the D4Z4 chromatin loop on FRG1 output unclear"]},{"year":2010,"claim":"Resolving FRG1's biochemical activity, purified human and C. elegans FRG1 were shown to bundle F-actin and to occupy both nucleolar and Z-disk pools, unifying its cytoplasmic and nuclear localizations.","evidence":"In vitro F-actin bundling assays for both orthologs, immunofluorescence in C. elegans muscle, transgenic overexpression","pmids":["20215405"],"confidence":"High","gaps":["How actin bundling relates to splicing function not established","Regulation of partitioning between pools unknown"]},{"year":2011,"claim":"Mammalian studies confirmed FRG1 shuttles between linked nuclear and cytoplasmic pools, redistributes to Z-discs on differentiation, and that its overexpression slows myoblast proliferation via reduced pRb phosphorylation.","evidence":"Nuclear shuttling assay, ICC, isolated myofiber and human biopsy staining; inducible C2C12 overexpression with cell cycle/pRb analysis","pmids":["20970242","21603621"],"confidence":"Medium","gaps":["Signal directing shuttling not defined","Link between proliferation defect and dystrophy not yet causal"]},{"year":2013,"claim":"Identifying the splicing mechanism, FRG1 was shown to destabilize Rbfox1 RNA and thereby mis-splice Calpain 3 and Tnnt3, with the Tnnt3 isoform shift causally reducing fiber Ca2+ sensitivity.","evidence":"RNA-IP, genome-wide splicing analysis, Rbfox1 knockdown, contractility/Ca2+ sensitivity assay with troponin substitution rescue, FSHD patient validation","pmids":["23300487","24305066"],"confidence":"High","gaps":["Direct RNA-binding mode of FRG1 not structurally defined","Whether FRG1 acts on additional splicing regulators beyond Rbfox1 unknown"]},{"year":2015,"claim":"Pinpointing the cellular lesion in FRG1 dystrophy, genetic rescue by fusion-promoting FHL1 showed that impaired myoblast fusion, not satellite cell loss, drives the phenotype.","evidence":"Stable C2C12 overexpression, FRG1 x FHL1 transgenic cross, histopathology, satellite cell and fusion assays","pmids":["25695429"],"confidence":"Medium","gaps":["Molecular fusion machinery affected by FRG1 not identified","Connection between fusion defect and aberrant splicing not mapped"]},{"year":2022,"claim":"Extending FRG1 to direct transcriptional control, it was shown to bind the GM-CSF promoter to repress cytokine-driven ERK signaling and to bind a CTGGG motif in NMD gene promoters.","evidence":"ChIP, reporter assays, EMSA, site-directed mutagenesis, signaling western blots, xenograft models","pmids":["36329016","36521634"],"confidence":"Medium","gaps":["Whether transcriptional and splicing roles are mechanistically coupled unclear","Genome-wide promoter occupancy not mapped"]},{"year":2023,"claim":"Defining FRG1's angiogenic mechanism in cancer, its depletion was shown to activate FGF2 and trigger paracrine ERK/AKT signaling in endothelial cells.","evidence":"HUVEC co-culture paracrine assay, FGF2 analysis, ERK/AKT western blot, FRG1 knockdown, in vivo angiogenesis models","pmids":["36815234"],"confidence":"Medium","gaps":["Whether FGF2 is a direct FRG1 transcriptional target untested","Relevance of this axis to developmental vasculature unclear"]},{"year":2024,"claim":"Promoter dissection showed FRG1's own transcription is set by competing Sp1, YY1 and DUX4 inputs that physically interact, linking FRG1 dosage to the FSHD effector DUX4.","evidence":"Dual luciferase, mutagenesis, ChIP-qPCR, EMSA, sequential ChIP, co-IP, xenograft","pmids":["39708975"],"confidence":"Medium","gaps":["In vivo contribution of each factor to FSHD-relevant FRG1 levels unquantified","Connection to D4Z4 chromatin loop not integrated"]},{"year":2024,"claim":"A correlative study linked low FRG1 to reduced base excision repair gene expression and impaired DNA repair capacity in breast cancer.","evidence":"qRT-PCR, Alkaline Comet Assay, bioinformatic mutation analysis","pmids":["39169067"],"confidence":"Low","gaps":["Mechanism linking FRG1 to BER gene transcription not directly demonstrated; indirect evidence only","No direct promoter binding shown for BER genes"]},{"year":2025,"claim":"Connecting FRG1 to the RNA surveillance machinery, it was placed as a component of the spliceosome and EJC that binds eIF4A3 and UPF1 and controls UPF1 ubiquitination to tune NMD, with DUX4 inversely regulating NMD via FRG1.","evidence":"Polysome profiling, PLA, Co-IP, ubiquitination and NMD reporter assays, FRG1 knockout zebrafish (preprint)","pmids":["bio_10.1101_2025.11.18.689056"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Whether FRG1 transcriptional repression of NMD genes and direct UPF1 control act on the same outputs unresolved"]},{"year":null,"claim":"How FRG1's actin-bundling activity, its splicing/NMD functions, and its sequence-specific transcriptional regulation are integrated into a single coherent biochemical role remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model unifying actin binding, RNA binding, and DNA binding","Whether nuclear and cytoplasmic functions are sequentially coupled or independent is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[6]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[9,17]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[12,13,15]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,13]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,7]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[6]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[6,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6,7]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[9,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,13,15]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,4,11]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[2,10]}],"complexes":["spliceosome","exon junction complex (EJC)"],"partners":["EIF4A3","UPF1","RBFOX1","SP1","YY1","DUX4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14331","full_name":"Protein FRG1","aliases":["FSHD region gene 1 protein"],"length_aa":258,"mass_kda":29.2,"function":"Binds to mRNA in a sequence-independent manner. May play a role in regulation of pre-mRNA splicing or in the assembly of rRNA into ribosomal subunits. May be involved in mRNA transport. May be involved in epigenetic regulation of muscle differentiation through regulation of activity of the histone-lysine N-methyltransferase KMT5B","subcellular_location":"Nucleus, Cajal body; Nucleus, nucleolus; Cytoplasm; Cytoplasm, myofibril, sarcomere, Z line","url":"https://www.uniprot.org/uniprotkb/Q14331/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FRG1","classification":"Not Classified","n_dependent_lines":128,"n_total_lines":1165,"dependency_fraction":0.10987124463519313},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FRG1","total_profiled":1310},"omim":[{"mim_id":"619883","title":"GOLGI-ASSOCIATED RAB2B INTERACTOR FAMILY, MEMBER 3; GARIN3","url":"https://www.omim.org/entry/619883"},{"mim_id":"609032","title":"FSHD REGION GENE 2; FRG2","url":"https://www.omim.org/entry/609032"},{"mim_id":"606009","title":"DOUBLE HOMEOBOX PROTEIN 4; DUX4","url":"https://www.omim.org/entry/606009"},{"mim_id":"601278","title":"FSHD REGION GENE 1; FRG1","url":"https://www.omim.org/entry/601278"},{"mim_id":"158900","title":"FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1","url":"https://www.omim.org/entry/158900"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FRG1"},"hgnc":{"alias_symbol":["FSG1","FRG1A"],"prev_symbol":[]},"alphafold":{"accession":"Q14331","domains":[{"cath_id":"2.80.10.50","chopping":"42-181","consensus_level":"high","plddt":87.1941,"start":42,"end":181},{"cath_id":"-","chopping":"195-250","consensus_level":"high","plddt":68.4513,"start":195,"end":250}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14331","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14331-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14331-F1-predicted_aligned_error_v6.png","plddt_mean":75.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FRG1","jax_strain_url":"https://www.jax.org/strain/search?query=FRG1"},"sequence":{"accession":"Q14331","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14331.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14331/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14331"}},"corpus_meta":[{"pmid":"16341202","id":"PMC_16341202","title":"Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16341202","citation_count":170,"is_preprint":false},{"pmid":"8733123","id":"PMC_8733123","title":"Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35.","date":"1996","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8733123","citation_count":107,"is_preprint":false},{"pmid":"19607661","id":"PMC_19607661","title":"Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation.","date":"2009","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/19607661","citation_count":74,"is_preprint":false},{"pmid":"19383939","id":"PMC_19383939","title":"FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy.","date":"2009","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19383939","citation_count":44,"is_preprint":false},{"pmid":"19097195","id":"PMC_19097195","title":"Muscular dystrophy candidate gene FRG1 is critical for muscle development.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19097195","citation_count":42,"is_preprint":false},{"pmid":"18852887","id":"PMC_18852887","title":"A functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18852887","citation_count":35,"is_preprint":false},{"pmid":"21730972","id":"PMC_21730972","title":"RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1).","date":"2011","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21730972","citation_count":34,"is_preprint":false},{"pmid":"9714712","id":"PMC_9714712","title":"FRG1, a gene in the FSH muscular dystrophy region on human chromosome 4q35, is highly conserved in vertebrates and invertebrates.","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9714712","citation_count":32,"is_preprint":false},{"pmid":"20215405","id":"PMC_20215405","title":"Facioscapulohumeral muscular dystrophy region gene-1 (FRG-1) is an actin-bundling protein associated with muscle-attachment sites.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/20215405","citation_count":32,"is_preprint":false},{"pmid":"23300487","id":"PMC_23300487","title":"Rbfox1 downregulation and altered calpain 3 splicing by FRG1 in a mouse model of Facioscapulohumeral muscular dystrophy (FSHD).","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23300487","citation_count":31,"is_preprint":false},{"pmid":"25425661","id":"PMC_25425661","title":"SNF2 chromatin remodeler-family proteins FRG1 and -2 are required for RNA-directed DNA methylation.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25425661","citation_count":29,"is_preprint":false},{"pmid":"20970242","id":"PMC_20970242","title":"Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric protein.","date":"2011","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/20970242","citation_count":23,"is_preprint":false},{"pmid":"30975102","id":"PMC_30975102","title":"Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30975102","citation_count":22,"is_preprint":false},{"pmid":"9931447","id":"PMC_9931447","title":"Recent amplification of the human FRG1 gene during primate evolution.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9931447","citation_count":22,"is_preprint":false},{"pmid":"24305066","id":"PMC_24305066","title":"Altered Tnnt3 characterizes selective weakness of fast fibers in mice overexpressing FSHD region gene 1 (FRG1).","date":"2013","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24305066","citation_count":19,"is_preprint":false},{"pmid":"26942723","id":"PMC_26942723","title":"Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26942723","citation_count":14,"is_preprint":false},{"pmid":"21603621","id":"PMC_21603621","title":"Decreased proliferation kinetics of mouse myoblasts overexpressing FRG1.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21603621","citation_count":12,"is_preprint":false},{"pmid":"9166581","id":"PMC_9166581","title":"The mouse homolog of FRG1, a candidate gene for FSHD, maps proximal to the myodystrophy mutation on chromosome 8.","date":"1997","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/9166581","citation_count":10,"is_preprint":false},{"pmid":"22343158","id":"PMC_22343158","title":"Effects of creatine and exercise on skeletal muscle of FRG1-transgenic mice.","date":"2012","source":"The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques","url":"https://pubmed.ncbi.nlm.nih.gov/22343158","citation_count":8,"is_preprint":false},{"pmid":"36815234","id":"PMC_36815234","title":"Reduced FRG1 expression promotes angiogenesis via activation of the FGF2-mediated ERK/AKT pathway.","date":"2023","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/36815234","citation_count":7,"is_preprint":false},{"pmid":"36329016","id":"PMC_36329016","title":"Reduced expression of FRG1 facilitates breast cancer progression via GM-CSF/MEK-ERK axis by abating FRG1 mediated transcriptional repression of GM-CSF.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36329016","citation_count":7,"is_preprint":false},{"pmid":"25695429","id":"PMC_25695429","title":"FHL1 reduces dystrophy in transgenic mice overexpressing FSHD muscular dystrophy region gene 1 (FRG1).","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25695429","citation_count":7,"is_preprint":false},{"pmid":"36521634","id":"PMC_36521634","title":"FRG1 is a direct transcriptional regulator of nonsense-mediated mRNA decay genes.","date":"2022","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/36521634","citation_count":6,"is_preprint":false},{"pmid":"27234941","id":"PMC_27234941","title":"Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) expression and possible function in mouse tooth germ development.","date":"2016","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/27234941","citation_count":6,"is_preprint":false},{"pmid":"34795329","id":"PMC_34795329","title":"Role of FRG1 in predicting the overall survivability in cancers using multivariate based optimal model.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34795329","citation_count":5,"is_preprint":false},{"pmid":"39708975","id":"PMC_39708975","title":"Dynamic interplay of Sp1, YY1, and DUX4 in regulating FRG1 transcription with intricate balance.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39708975","citation_count":2,"is_preprint":false},{"pmid":"39169067","id":"PMC_39169067","title":"Unveiling FRG1's DNA repair role in breast cancer.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39169067","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.18.689056","title":"FRG1 Regulates Nonsense-Mediated mRNA Decay by Modulating UPF1 Levels","date":"2025-11-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.18.689056","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16214,"output_tokens":4930,"usd":0.061296,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13041,"output_tokens":4345,"usd":0.086915,"stage2_stop_reason":"end_turn"},"total_usd":0.148211,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"FRG1 is a novel gene located ~100 kb proximal to the D4Z4 repeat on chromosome 4q35, encoding a 258 amino acid protein with a CpG island at its 5' UTR; allele-specific RNA-SSCP analysis found no evidence for position-effect variegation-mediated repression of FRG1 transcription in FSHD lymphocytes or muscle.\",\n      \"method\": \"Molecular cloning, genomic mapping, RNA-SSCP allele-specific expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — original identification with multiple molecular methods (cloning, mapping, SSCP), single lab, foundational characterization\",\n      \"pmids\": [\"8733123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FRG1 protein contains a lipocalin sequence motif, suggesting it may function as a transport protein; the intron/exon structure of FRG1 is conserved across vertebrates (human, mouse, Fugu) and nematodes (C. elegans, Brugia malayi).\",\n      \"method\": \"Comparative genomic cloning, sequence alignment, motif analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational/sequence-based motif prediction only, no functional validation of transport activity\",\n      \"pmids\": [\"9714712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Transgenic mice selectively overexpressing FRG1 in skeletal muscle develop a muscular dystrophy with features characteristic of FSHD, including aberrant alternative splicing of specific pre-mRNAs in both FRG1 transgenic mouse muscle and FSHD patient muscle; FRG1 is a nuclear protein implicated in pre-mRNA splicing. Overexpression of FRG2 or ANT1 did not produce this phenotype.\",\n      \"method\": \"Transgenic mouse generation (skeletal muscle-specific overexpression), histopathology, RT-PCR splicing analysis, nuclear localization by immunostaining\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple transgenic lines with genetic controls (FRG2, ANT1 transgenics), replicated in human FSHD patient samples, two orthogonal readouts (muscle phenotype + splicing)\",\n      \"pmids\": [\"16341202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Endogenous frg1 in Xenopus is expressed in developing and adult vasculature; frg1 knockdown reduces angiogenesis and decreases expression of the angiogenic regulator DAB2, while frg1 overexpression causes increased blood vessel branching, dilation, and edema.\",\n      \"method\": \"Xenopus morpholino knockdown, overexpression, in vivo angiogenesis assay, DAB2 expression analysis\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function in Xenopus with defined vascular phenotype and downstream target (DAB2), single lab\",\n      \"pmids\": [\"19383939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"frg1 is expressed in Xenopus tadpole musculature and is essential for myotome development; morpholino-mediated frg1 knockdown disrupts myotome organization and inhibits myotome growth, while FRG1 overexpression causes abnormal epaxial and hypaxial muscle formation.\",\n      \"method\": \"Xenopus morpholino knockdown, mRNA overexpression, histological analysis of myotome\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal loss-of-function and gain-of-function with defined morphological readout, single lab\",\n      \"pmids\": [\"19097195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The FRG1 gene promoter and the D4Z4 array physically interact in cis, as demonstrated by chromosome conformation capture (3C); this chromatin loop undergoes dynamic changes during myogenic differentiation (loosening in myotubes). FRG1 promoter is marked by H3K27 trimethylation and Polycomb repressor complex binding in myoblasts, replaced by H3K4 trimethylation upon differentiation. FRG1 is prematurely expressed during FSHD myoblast differentiation.\",\n      \"method\": \"Chromosome conformation capture (3C), ChIP for H3K27me3, H3K4me3, Polycomb complex; RT-PCR expression analysis\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3C plus ChIP with multiple histone marks, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19607661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"C. elegans FRG-1 and human FRG1 are F-actin-bundling proteins; C. elegans FRG-1 localizes to two subcellular pools: nuclear (nucleolar) and cytoplasmic (Z-disk/dense body structures). Overexpressed FRG-1 preferentially accumulates in the nucleus and, when overexpressed from the frg-1 promoter, disrupts adult ventral muscle structure and organization.\",\n      \"method\": \"In vitro F-actin bundling assay (with both C. elegans and human FRG1), immunofluorescence localization in C. elegans body-wall muscle, transgenic C. elegans overexpression\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro actin bundling assay directly demonstrated for both C. elegans and human FRG1, complemented by subcellular localization and in vivo functional data in C. elegans\",\n      \"pmids\": [\"20215405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FRG1 is a dynamic nuclear and cytoplasmic protein in mammalian cells; nuclear shuttling assays show the subcellular pools are linked. During myoblast differentiation, FRG1 redistributes to mature Z-discs, as confirmed in isolated mouse myofibers and adult human skeletal muscle biopsies. FRG1 is also strongly expressed in arteries, veins, and capillaries.\",\n      \"method\": \"Immunocytochemistry, nuclear shuttling assay (heterokaryon or similar), isolated myofiber immunostaining, human muscle biopsy histology\",\n      \"journal\": \"Differentiation; research in biological diversity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by ICC plus nuclear shuttling assay with functional context (sarcomere association), validated in mouse and human tissue, single lab\",\n      \"pmids\": [\"20970242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FRG1 overexpression in C2C12 myoblasts reduces pRb phosphorylation, increases G1-phase cells, and increases doubling time; myoblasts from dystrophic (thigh) muscle of FRG1 transgenic mice show decreased proliferative capacity, while myoblasts from unaffected (diaphragm) muscle proliferate normally.\",\n      \"method\": \"Inducible FRG1 overexpression in C2C12, flow cytometry cell cycle analysis, pRb phosphorylation by western blot, clone-size assay from primary myoblasts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent cell systems (inducible C2C12 and primary myoblasts), cell cycle analysis with molecular correlate (pRb phosphorylation), single lab\",\n      \"pmids\": [\"21603621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FRG1 overexpression reduces Rbfox1 RNA stability, leading to downregulation of Rbfox1 protein; this results in aberrant splicing of Rbfox1 target genes including Calpain 3 (increased exon-6-skipped isoform Capn3 E6-). FRG1 was found to be associated with Rbfox1 RNA by RNA-IP. Rbfox1 knockdown and Capn3 E6- overexpression each inhibit muscle differentiation.\",\n      \"method\": \"RNA-IP (FRG1 association with Rbfox1 RNA), genome-wide splicing analysis, Rbfox1 knockdown, RT-PCR splicing assays, muscle differentiation assays, FSHD patient validation\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — RNA-IP plus genome-wide splicing analysis plus knockdown/overexpression rescue experiments, validated in FSHD patient samples, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"23300487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FRG1-overexpressing mice develop aberrant splicing of Tnnt3 (fast skeletal troponin T), producing anomalous fTnT isoforms before dystrophic signs appear; fast-twitch fibers in these mice show reduced Ca2+ sensitivity that can be rescued by substitution with wild-type troponin complex proteins. Aberrant TNNT3 splicing isoforms are also present in FSHD patient muscles.\",\n      \"method\": \"RT-PCR splicing analysis, muscle contractility/Ca2+ sensitivity assay, protein substitution rescue experiment, FSHD patient sample validation\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution/substitution rescue of Ca2+ sensitivity, combined with splicing analysis and human patient validation, multiple orthogonal methods\",\n      \"pmids\": [\"24305066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FRG1 overexpression causes a myoblast fusion defect in C2C12 cells; crossing FRG1 transgenic mice with FHL1 transgenic mice (which promote myoblast fusion) rescues the dystrophic phenotype (reduced kyphosis, increased muscle mass, decreased fibrosis) without altering satellite cell number or activation, establishing that impaired myoblast fusion contributes to FRG1-mediated dystrophy.\",\n      \"method\": \"Stable C2C12 overexpression, transgenic cross (FRG1 x FHL1 mice), histopathology, satellite cell analysis, primary myoblast fusion assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via transgenic cross with defined cellular mechanism (myoblast fusion), validated in primary cells and in vivo, single lab\",\n      \"pmids\": [\"25695429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FRG1 directly binds the GM-CSF promoter to repress its transcription; FRG1 depletion increases GM-CSF expression, which activates the MEK/ERK axis and inhibits p53-dependent apoptosis in breast cancer cells in an ERK-dependent manner.\",\n      \"method\": \"ChIP, promoter reporter assay, western blot (MEK/ERK, p53), GM-CSF knockdown rescue, mouse xenograft model, anti-GM-CSF mAb treatment\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct FRG1 binding to GM-CSF promoter, functional pathway validated by pharmacological inhibition and in vivo xenograft, single lab\",\n      \"pmids\": [\"36329016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FRG1 acts as a transcriptional regulator of nonsense-mediated mRNA decay (NMD) pathway genes (UPF1, UPF3B, SMG1) by binding to a conserved 'CTGGG' motif in their promoters; this was established by structural modeling, EMSA, ChIP-qPCR, and luciferase reporter assays.\",\n      \"method\": \"Microarray expression profiling, structural modeling, EMSA, ChIP-qPCR, luciferase reporter assay, site-directed mutagenesis (predicted binding site)\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (EMSA, ChIP, luciferase, mutagenesis) supporting direct DNA binding and transcriptional regulation, single lab\",\n      \"pmids\": [\"36521634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FRG1 depletion in breast cancer cells activates FGF2 expression, which in turn triggers ERK/AKT signaling in endothelial cells (HUVECs) to enhance proliferation, migration, and tubule formation in a paracrine manner; this pro-angiogenic effect was validated in multiple animal models.\",\n      \"method\": \"HUVEC co-culture paracrine assay, FGF2 expression analysis, western blot (ERK/AKT), FRG1 knockdown, in vivo animal angiogenesis models\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — paracrine mechanism with defined intermediary (FGF2) validated in multiple animal models, single lab, mechanistic pathway defined by signaling analysis\",\n      \"pmids\": [\"36815234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FRG1 transcription is regulated by Sp1 (activator), YY1 (repressor), and DUX4 (activator) binding to cis-regulatory elements in the FRG1 promoter; YY1 can suppress Sp1- or DUX4-mediated FRG1 transcription activation, while Sp1 and DUX4 together counteract YY1-mediated repression. Sp1, YY1, and DUX4 physically interact with each other at the FRG1 promoter.\",\n      \"method\": \"Dual luciferase reporter assay, site-directed mutagenesis, ChIP-qPCR, EMSA, sequential ChIP (ChIP re-ChIP), co-immunoprecipitation, mouse xenograft model\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (EMSA, ChIP, co-IP, mutagenesis, reporter assay) establishing direct binding and functional interactions, single lab\",\n      \"pmids\": [\"39708975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FRG1 affects transcription of DNA base excision repair (BER) genes including HPF1; breast cancer cells with reduced FRG1 show diminished DNA repair capacity as measured by Alkaline Comet Assay, and FRG1-low breast cancers have higher TP53 mutation frequency.\",\n      \"method\": \"qRT-PCR, Alkaline Comet Assay, bioinformatic analysis of mutation frequency\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, Comet Assay provides functional readout but mechanism linking FRG1 to BER gene transcription not directly demonstrated; indirect evidence only\",\n      \"pmids\": [\"39169067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FRG1 is a structural component of both the spliceosome and the exon junction complex (EJC), co-sedimenting with the core EJC component eIF4A3 in polysome fractions; FRG1 directly interacts with UPF1 and regulates its ubiquitination and degradation, thereby modulating NMD activity. Reduced FRG1 enhances NMD activity. DUX4 inversely regulates NMD machinery through FRG1. Absence of FRG1 does not compromise EJC or spliceosome integrity. These findings were validated in a transgenic FRG1 knockout zebrafish model.\",\n      \"method\": \"Polysome profiling, proximity ligation assay (FRG1-eIF4A3 interaction), co-immunoprecipitation (FRG1-UPF1), ubiquitination assay, NMD reporter assay, FRG1 knockout zebrafish in vivo validation\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — preprint with multiple orthogonal methods (polysome profiling, PLA, Co-IP, ubiquitination assay, in vivo zebrafish KO), single lab, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.11.18.689056\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"FRG1 is a dual-compartment protein (nuclear and sarcomeric/cytoplasmic) that functions in pre-mRNA splicing and post-transcriptional regulation: it directly bundles F-actin at Z-discs/dense bodies, associates with the spliceosome and exon junction complex (interacting with eIF4A3 and UPF1 to modulate nonsense-mediated mRNA decay), regulates alternative splicing of muscle-specific transcripts (e.g., TNNT3, Calpain 3) partly by destabilizing the splicing regulator Rbfox1, acts as a transcriptional repressor of cytokines (GM-CSF) and NMD pathway genes via direct promoter binding, and controls angiogenesis through a FGF2-ERK/AKT paracrine axis; its overexpression in skeletal muscle causes FSHD-like muscular dystrophy via aberrant splicing and impaired myoblast fusion, while its transcription is controlled by the interplay of Sp1 (activator), YY1 (repressor), and DUX4 (activator) at its promoter.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FRG1 is a dual-compartment protein that couples cytoskeletal organization to post-transcriptional gene regulation, and its dysregulation underlies muscle and vascular pathology [#2, #6, #9]. In the cytoplasm it directly bundles F-actin and localizes to Z-disc/dense-body structures, redistributing to mature Z-discs during myoblast differentiation [#6, #7]. In the nucleus FRG1 participates in pre-mRNA splicing and post-transcriptional control: it associates with Rbfox1 RNA and destabilizes it, driving aberrant alternative splicing of muscle transcripts including Calpain 3 and the fast troponin T gene Tnnt3, the latter producing fibers with reduced Ca2+ sensitivity [#9, #10]. FRG1 also acts as a sequence-specific transcriptional regulator, binding the GM-CSF promoter to repress cytokine expression and ERK signaling, and binding a conserved CTGGG motif in the promoters of NMD genes UPF1, UPF3B and SMG1 [#12, #13]. Selective overexpression of FRG1 in skeletal muscle causes an FSHD-like muscular dystrophy with aberrant splicing recapitulated in FSHD patient muscle, mechanistically attributable to impaired myoblast fusion, since restoring fusion via FHL1 rescues the dystrophic phenotype [#2, #11]. FRG1 transcription is itself controlled by competing promoter factors Sp1, YY1 and DUX4 that physically interact at the FRG1 promoter, and the FRG1 promoter loops to the D4Z4 array in a differentiation-dependent manner [#15, #5]. FRG1 additionally controls angiogenesis through a paracrine FGF2-ERK/AKT axis [#14, #3].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing FRG1 as a defined gene near the FSHD-associated D4Z4 repeat created the genomic entry point, while showing its transcription is not silenced by position effect in patient tissue.\",\n      \"evidence\": \"Molecular cloning, genomic mapping, and allele-specific RNA-SSCP in FSHD lymphocytes and muscle\",\n      \"pmids\": [\"8733123\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No protein function assigned\", \"Relationship between FRG1 and FSHD pathogenesis not yet tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Asking whether FRG1 itself could drive FSHD pathology, muscle-specific overexpression in mice produced a dystrophy with aberrant splicing matching FSHD patient muscle, implicating FRG1 in pre-mRNA splicing.\",\n      \"evidence\": \"Skeletal-muscle-specific transgenic mice with FRG2/ANT1 transgenic controls, histopathology, RT-PCR splicing analysis, nuclear immunostaining\",\n      \"pmids\": [\"16341202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular splicing target not yet identified\", \"Mechanism connecting FRG1 to spliceosome unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Vertebrate and chromatin studies expanded FRG1 beyond muscle, showing roles in angiogenesis and myotome development and that its promoter loops to D4Z4 with differentiation-dependent histone marks.\",\n      \"evidence\": \"Xenopus morpholino knockdown/overexpression with vascular and myotome readouts; 3C and ChIP for H3K27me3/H3K4me3/Polycomb in myoblasts\",\n      \"pmids\": [\"19383939\", \"19097195\", \"19607661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether vascular and muscle roles share a molecular mechanism unresolved\", \"Functional consequence of the D4Z4 chromatin loop on FRG1 output unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Resolving FRG1's biochemical activity, purified human and C. elegans FRG1 were shown to bundle F-actin and to occupy both nucleolar and Z-disk pools, unifying its cytoplasmic and nuclear localizations.\",\n      \"evidence\": \"In vitro F-actin bundling assays for both orthologs, immunofluorescence in C. elegans muscle, transgenic overexpression\",\n      \"pmids\": [\"20215405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How actin bundling relates to splicing function not established\", \"Regulation of partitioning between pools unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mammalian studies confirmed FRG1 shuttles between linked nuclear and cytoplasmic pools, redistributes to Z-discs on differentiation, and that its overexpression slows myoblast proliferation via reduced pRb phosphorylation.\",\n      \"evidence\": \"Nuclear shuttling assay, ICC, isolated myofiber and human biopsy staining; inducible C2C12 overexpression with cell cycle/pRb analysis\",\n      \"pmids\": [\"20970242\", \"21603621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal directing shuttling not defined\", \"Link between proliferation defect and dystrophy not yet causal\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying the splicing mechanism, FRG1 was shown to destabilize Rbfox1 RNA and thereby mis-splice Calpain 3 and Tnnt3, with the Tnnt3 isoform shift causally reducing fiber Ca2+ sensitivity.\",\n      \"evidence\": \"RNA-IP, genome-wide splicing analysis, Rbfox1 knockdown, contractility/Ca2+ sensitivity assay with troponin substitution rescue, FSHD patient validation\",\n      \"pmids\": [\"23300487\", \"24305066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA-binding mode of FRG1 not structurally defined\", \"Whether FRG1 acts on additional splicing regulators beyond Rbfox1 unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Pinpointing the cellular lesion in FRG1 dystrophy, genetic rescue by fusion-promoting FHL1 showed that impaired myoblast fusion, not satellite cell loss, drives the phenotype.\",\n      \"evidence\": \"Stable C2C12 overexpression, FRG1 x FHL1 transgenic cross, histopathology, satellite cell and fusion assays\",\n      \"pmids\": [\"25695429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular fusion machinery affected by FRG1 not identified\", \"Connection between fusion defect and aberrant splicing not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extending FRG1 to direct transcriptional control, it was shown to bind the GM-CSF promoter to repress cytokine-driven ERK signaling and to bind a CTGGG motif in NMD gene promoters.\",\n      \"evidence\": \"ChIP, reporter assays, EMSA, site-directed mutagenesis, signaling western blots, xenograft models\",\n      \"pmids\": [\"36329016\", \"36521634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether transcriptional and splicing roles are mechanistically coupled unclear\", \"Genome-wide promoter occupancy not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defining FRG1's angiogenic mechanism in cancer, its depletion was shown to activate FGF2 and trigger paracrine ERK/AKT signaling in endothelial cells.\",\n      \"evidence\": \"HUVEC co-culture paracrine assay, FGF2 analysis, ERK/AKT western blot, FRG1 knockdown, in vivo angiogenesis models\",\n      \"pmids\": [\"36815234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FGF2 is a direct FRG1 transcriptional target untested\", \"Relevance of this axis to developmental vasculature unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Promoter dissection showed FRG1's own transcription is set by competing Sp1, YY1 and DUX4 inputs that physically interact, linking FRG1 dosage to the FSHD effector DUX4.\",\n      \"evidence\": \"Dual luciferase, mutagenesis, ChIP-qPCR, EMSA, sequential ChIP, co-IP, xenograft\",\n      \"pmids\": [\"39708975\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo contribution of each factor to FSHD-relevant FRG1 levels unquantified\", \"Connection to D4Z4 chromatin loop not integrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A correlative study linked low FRG1 to reduced base excision repair gene expression and impaired DNA repair capacity in breast cancer.\",\n      \"evidence\": \"qRT-PCR, Alkaline Comet Assay, bioinformatic mutation analysis\",\n      \"pmids\": [\"39169067\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mechanism linking FRG1 to BER gene transcription not directly demonstrated; indirect evidence only\", \"No direct promoter binding shown for BER genes\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connecting FRG1 to the RNA surveillance machinery, it was placed as a component of the spliceosome and EJC that binds eIF4A3 and UPF1 and controls UPF1 ubiquitination to tune NMD, with DUX4 inversely regulating NMD via FRG1.\",\n      \"evidence\": \"Polysome profiling, PLA, Co-IP, ubiquitination and NMD reporter assays, FRG1 knockout zebrafish (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.11.18.689056\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Whether FRG1 transcriptional repression of NMD genes and direct UPF1 control act on the same outputs unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FRG1's actin-bundling activity, its splicing/NMD functions, and its sequence-specific transcriptional regulation are integrated into a single coherent biochemical role remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model unifying actin binding, RNA binding, and DNA binding\", \"Whether nuclear and cytoplasmic functions are sequentially coupled or independent is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [9, 17]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [12, 13, 15]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [9, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 13, 15]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 4, 11]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [2, 10]}\n    ],\n    \"complexes\": [\"spliceosome\", \"exon junction complex (EJC)\"],\n    \"partners\": [\"eIF4A3\", \"UPF1\", \"Rbfox1\", \"Sp1\", \"YY1\", \"DUX4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}